Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Serono, Illumina team up to advance precision medicine

This article was originally published in Clinica

Executive Summary

Merck Serono is to collaborate with Illumina on the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies. The companies aim to develop assays to detect and simultaneously measure multiple genetic variants in a single tumor sample in a clinical trial setting. The agreement includes development of the diagnostic, worldwide regulatory approvals and global commercialization, and is a "step forward in realizing the promise of precision medicine," said Dr Richard Klausner, Illumina's chief medical officer. Merck KGaA has existing partnerships in the area of diagnostics, including those with Life Technologies and Dako.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts